Document:

Unassociated Document

    EXHIBIT 10.23

    

    

    FIRST
      AMENDMENT

     

    TO

     

    TRANSITION
      AGREEMENT

     

    

    

    WHEREAS,
      a
      transition agreement (the “Agreement”) was entered into, effective as of August
      10, 2005, between Genentech, Inc., One DNA Way, South San Francisco, CA 94080,
      and Myrtle Potter;

    

    WHEREAS,
      Section
      6
      of the Agreement provides that the parties to the Agreement are to cooperate
      diligently and in good faith to take action to prevent the imposition of
      penalties under Section 409A of the Internal Revenue Code (“Section 409A
      Penalties”); and

    

    WHEREAS,
      the
      parties have decided to amend the Agreement as contemplated by Section 6 of
      the
      Agreement in order to avoid the imposition of Section 409A
      Penalties;

    

    WHEREAS,
      the
      parties understand that further action, or amendments to the Agreement, may
      need
      to be made to avoid Section 409A Penalties as provided in Section 6 of the
      Agreement;

    

    NOW,
      THEREFORE, the
      Agreement is hereby, amended effective August 10, 2005, as follows:

    

    I.

    

         Section
      5 is amended as
      follows:

    

        A. The
      second paragraph of Section 5 is amended to read as follows:

    

    Potter’s
      currently outstanding stock options granted to her under Genentech’s 1999 Stock
      Plan during the course of her employment will continue to vest and be
      exercisable during her term as a consultant in the same manner as they were
      during her employment. The stock options will cease to vest when her consultancy
      ends either at the end of its term as set forth in Section 1 above or upon
      its
      earlier termination as set forth in Section 1 above. Potter’s options granted on
      or after September 12, 2002 that are or become vested and exercisable shall
      be
      exercised in a cashless exercise in accordance with their terms as follows:
      All
      options granted on or after September 12, 2002 that become vested and
      exercisable on or after January 2, 2006 shall be exercised on January 2, 2006
      or
      the first trading day thereafter. Options granted on or after September 12,
      2002
      that are not vested and exercisable on January 2, 2006 shall be exercised on
      the
      first trading day after the date they first become vested and exercisable.
      For
      illustration, a schedule showing, with respect to options granted on or after
      September 12, 2002, exercise dates and 

    

    
      
        
        

      

      
        -1-

        
          

        

      

      
        
        

      

    

    

    number
      of
      options to be exercised is attached hereto as Exhibit A. Potter’s options
      granted prior to September 12, 2002 are the subject of a property settlement
      incident to divorce and will be exercised at the direction of James Potter
      pursuant to such settlement.

    

        B. The
      following sentence is added to the end of last paragraph of Section
      5:

    

    Notwithstanding
      the foregoing, Potter shall be paid her accrued SERP benefit with Genentech
      in a
      lump sum cash payment on February 13, 2006.

    

    II.

    

    The
      first
      paragraph of Section 6 is amended by adding the following sentence to the end
      thereof:

    

    Notwithstanding
      the foregoing provisions of this paragraph, in lieu of any and all information
      technology support and security services to be provided as described above
      after
      March 16, 2006, commencing on March 16, 2006, Genentech will instead provide
      to
      Potter during the term of her consultancy a monthly payment equal to fifty
      dollars ($50.00) payable March 16, 2006 and the 16th
      day of
      each subsequent month for the remainder of the term of the consulting
      relationship (with any payments for partial months to be prorated
      appropriately); provided that in the event the cost of such services to Potter
      exceeds $350.00 in the aggregate, Potter may request in advance that Genentech
      pay such excess. If Genentech approves Potter’s request, Genentech shall
      promptly pay Potter such excess.

    

    

    III.

    

    The
      following sentence is added to the end of Section 12:

    

    Notwithstanding
      the foregoing, any reimbursements for attorney’s fees and related costs incurred
      by Potter will be made on or before March 15, 2006.

    

    

    IV.

    

    A
      new
Exhibit
      A
      - Option
      Exercise Plan - is added to the end of the Agreement to read as provided in
      the
      attachment hereto.

    

    
      
        
        

      

      
        -2-

        
          

        

      

      
        
        

      

    

    

    V.

    

    Except
      as
      otherwise provided herein, the Agreement shall remain in full force and
      effect.

    

    This
      First Amendment to the Agreement may be executed in separate counterparts that
      together constitute one instrument.

    

    
      	 	 	 	
              GENENTECH,
                INC.

            
	 	 	 
	 	 	 	
              By:

            	
              /s/
                STEPHEN JUELSGAARD

            
	 	 	 	 	
              Stephen
                Juelsgaard

            
	 	 	 	 	 
	 	 	 	
              Date:

            	
                December
                28, 2005

            
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	
              MYRTLE
                POTTER

            
	 	 	 	 	 
	 	 	 	
              /s/
                MYRTLE POTTER

            
	 	 	 	 	 
	 	 	 	
              Date:

            	
                December
                29, 2005

            

    

    

    
      
        
        

      

      
        -3-Unassociated Document

    EXHIBIT 10.28

    

     

    FIRST
      AMENDMENT TO THE MANUFACTURING AND SUPPLY AGREEMENT

    DATED
      DECEMBER 7 2003

     

     

    THIS
      FIRST AMENDMENT TO THE MANUFACTURING AND SUPPLY AGREEMENT DATED DECEMBER 7
      2003
      ("Amendment") is made effective as of 14 March 2005 (the “Effective Date”), by
      and between Lonza Biologics PLC, having its principal place of business at
      228
      Bath Road, Slough, Berkshire SL1 4DX, England ("LB"), Lonza Biologics, Inc.
      having its principal place of business at 101 International Drive Portsmouth,
      New Hampshire 03801 ("Lonza Inc") (collectively LB and Lonza Inc, hereinafter
      "Lonza"), and Genentech, Inc., a Delaware corporation, having its principal
      place of business at One DNA Way, South San Francisco, California 94080
      ("Genentech").

     

    BACKGROUND

    

    The
      Parties have executed that certain Manufacturing and Supply Agreement by and
      between the Parties dated December 7, 2003 (“Agreement”) and wish now to amend
      said Agreement.

    

    Lonza
      desires to add a fourth bioreactor to the Lonza Facility.

    

    Genentech
      desires to utilize some of the capacity the fourth bioreactor will provide.
      

    

    NOW,
      THEREFORE, IN CONSIDERATION OF the mutual covenants set forth in this Agreement,
      and for other good and valuable consideration, the receipt and sufficiency
      of
      which are hereby acknowledged, the Parties hereby agree as follows:

    

    

    
      	
              1.
                

            	
              Installation
                of 4th Bioreactor.
                Lonza shall add a fourth bioreactor and associated equipment to the
                Lonza
                Facility.

            

    

    

    
      	
              2.
                

            	
              Validation
                of 4th Bioreactor.
                Following installation of such fourth bioreactor, Lonza shall use
                its
                Commercially Reasonable Best Efforts to validate such reactor for
                use with
                the Manufacturing Process and in order to commence Commercial Production
                of Bulk Drug (i.e., commencement of the first Commerical Run) with
                such
                fourth bioreactor, as soon as is reasonably practicable, but in any
                event
                no later than [*]
                Campaign,
                [*];
                provided,
                in no event shall Lonza take any action that would impair or delay
                its
                obligation to conduct Commercial Production of Bulk Drug in the existing
                reactors at the Lonza Facility and deliver Bulk Drug in the amounts
                and
                time frame specified in the Agreement. Lonza shall notify Genentech
                in
                writing promptly upon Lonza becoming aware of any such activity that
                may
                result in such impairment or delay, and shall not initiate any such
                activity without obtaining Genentech’s prior written review and
                approval.

            

    

    
      
        
        

      

      
        -1-

        
          

        

      

      
        
        

      

    

    

    
      	
              3.

            	
              Qualification
                Runs on 4th Bioreactor.
                Without limiting the foregoing, Lonza shall use Commercially Reasonable
                Best Efforts to perform [*]
                Qualification
                Runs to produce at least [*]
                on
                such fourth bioreactor by no later than [*]
                in
                this Section of the Amendment; provided, Genentech shall have no
                obligation to pay Lonza for more than [*].
                Subject
                to the foregoing, for each [*]
                manufactured
                on such fourth bioreactor in conformance with cGMP, the Bulk Drug
                Specifications, the Target Yield, and the warranties in Section 7.1,
                Genentech shall pay Lonza an amount equal to [*].
                Such
                amounts shall be the Purchase Price for such Qualifications Batches.
                Genentech may make whatever further uses of such Batches, including
                without limitation, any Product therefrom, as it shall determine
                is
                appropriate. Lonza shall use Commercially Reasonable Best Efforts
                to
                provide all the required documentation to Genentech to support the
                sBLA
                filing for the fourth bioreactor by no later than the [*]

            

    

    

    
      	
              4.

            	
              Commercial
                Production on 4th Bioreactor.
                Following the completion at commercial scale of at least [*]
                on
                such fourth bioreactor that complies with cGMP, the Bulk Drug
                Specifications, the Target Yield, and the warranties in Section 7.1,
                and
                execution and delivery by Lonza of the related Certificates of Compliance
                and Certificates of Testing, Genentech shall have the right to provide
                written notice to Lonza to commence, and following receipt of such
                notice
                Lonza shall commence, Commercial Production of Bulk Drug with such
                fourth
                bioreactor under this Agreement.

            

    

    

    
      	
              5.

            	
              Adjustments
                to Annual Minimums following Commencement of Commercial Production
                on the
                4th Bioreactor.
                Concurrent with the Calendar Quarter in which Commercial Production
                of
                Bulk Drug on such fourth bioreactor commences, the Campaign Minimum
                Runs
                and Successful Commercial Batches for such Calendar Quarter and each
                Calendar Quarter thereafter, as detailed in Exhibit A of the Agreement,
                shall be amended to [*]
                (i.e., as of the effective date of this Amendment,
                [*]

            

    

    

    
      	
              6.

            	
              Rescheduling
                of the [*] Campaigns.
                Notwithstanding the Campaign, Campaign Minimum and Campaign Minimum
                Run
                schedule listed on Exhibit A: 

            

    

     

    (i)
      the [*]Campaign
      scheduled to commence in the [*]
      shall be rescheduled to the [*]
      such Campaign to commence on [*]
      and
      continue for a [*]
      during
      which time Lonza shall be obligated to perform [*]Campaign
      Minimum Runs;

     

    (ii)
      the [*]Campaigns
      scheduled for the [*]
      and
      shall be rescheduled to the [*]
      such Campaign to commence on [*]
      and continue
      for a [*]
      during
      which time Lonza shall be obligated to perform [*]
      campaign
      Minimum Runs. It is the expectation of the Parties that [*]
      campaign
      Minimum Runs shall be allocated to conducting the [*]
      on the fourth bioreactor, as further described in Section 3 above;
      and

    
      
        
        

      

      
        -2-

        
          

        

      

      
        
        

      

    

     

    

     

    (iii)
      the [*]
      Campaign
      scheduled for the [*]
      shall
      be rescheduled to commence on [*]
      and
      continue for a Campaign [*]
      during
      which time Lonza shall be obligated to perform [*]
      Campaign
      Minimum Runs.

    

    
      	
              7.

            	
              Cross-Contamination.
                In order to minimize the risk of cross-contamination of Product with
                another product at the Lonza Facility, during the period of time
                that
                Lonza is processing any Bulk Drug in any of the existing bioreactors
                at
                the Lonza Facility, Lonza shall not introduce or process any other
                product
                in the fourth bioreactor after the process piping of such fourth
                bioreactor is connected to the existing
                bioreactors.

            

    

    

    
      	
              8
                

            	
              Genentech
                [*] 4th Bioreactor. With
                respect to [*.]

            

    

    

    
      	
              9.

            	
              All
                terms and conditions of the Agreement not modified by this Amendment
                shall
                continue in full force and effect. All capitalized terms not otherwise
                defined herein shall have the same definition as in the
                Agreement.

            

    

    

    
      
        
        

      

      
        -3-

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the Parties have caused this Amendment to be executed as of
      the
      Effective Date.

    

    
      	
              GENENTECH,
                INC.

            	 
	 	 	 
	
              By:

            	
              /s/
                DAVID EBERSMAN

            	 
	 	 	 
	
              Name:

            	
              David
                Ebersman

            	 
	
              Title:

            	
              Senior
                Vice President, Finance

            	 
	 	 	 
	 	 	 
	
              By:

            	
              /s/
                PAT YANG

            	 
	 	 	 
	
              Name:

            	
              Pat
                Yang

            	 
	
              Title:

            	
              Senior
                Vice President, Product Operations

            	 
	 	 	 
	 	 	 
	
              LONZA
                BIOLOGICS, INC.

            	 
	 	 	 
	
              By:

            	
              /s/
                GERHARD KLEMENT

            	 
	 	 	 
	
              Name:

            	
              Gerhard
                Klement

            	 
	
              Title:

            	
              Chief
                Operating Officer

            	 
	 	 	 
	
              LONZA
                BIOLOGICS, PLC

            	 
	 	 	 
	
              By:

            	
              /s/
                GERHARD KLEMENT

            	 
	 	 	 
	
              Name:

            	
              Gerhard
                Klement

            	 
	
              Title:

            	
              Chief
                Operating Officer

            	 

    

    

    
      
        
        

      

      
        -4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]